Chandra Bhagat Pharma Ltd (542934)
🎯 Key Takeaways
- Chandra Bhagat Pharma Ltd appears to be in a consolidation and capital restructuring phase, with management focusing on strategic approvals at the 23rd AGM including reappointment of key leadership and expansion of authorized capital. The company maintains a conservative balance sheet with low leverage (D/E 0.
- ⚠️ 1) High promoter concentration (73%) increases governance and control risk. 2) Absence of institutional or DII interest may signal lack of confidence
📖 The Story
Chandra Bhagat Pharma Ltd appears to be in a consolidation and capital restructuring phase, with management focusing on strategic approvals at the 23rd AGM including reappointment of key leadership and expansion of authorized capital. The company maintains a conservative balance sheet with low leverage (D/E 0.50) and stable asset base, while shareholding shows promoter dominance and minimal institutional participation. Recent financial trends indicate modest operating cash flow generation but no significant capital investment activity.
📰 What's Happening
The 23rd AGM on September 1, 2026 approved the annual accounts, reappointed Pragyan Hemant Bhagat, increased authorized share capital, and authorized issuance of up to 66 lakh convertible warrants. Management indicated voting results would be announced within two working days and published on the company website. This capital action suggests preparation for potential future fundraising or acquisition activity, though no specific use of funds was disclosed.
Source: Stock Announcements
🔮 Management Outlook & What's Next
Management did not provide forward guidance during the AGM, merely stating that voting results would be announced within two working days. No commentary on future profitability, revenue growth, or capital allocation plans beyond the approved warrant issuance was shared in the filing. The lack of strategic outlook beyond routine approvals suggests limited near-term visibility on growth initiatives.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2026 | Mar 2026 |
|---|---|---|
| Equity Capital | 8 | 8 |
| Reserves | 23 | 26 |
| Borrowings | 21 | 17 |
| Total Liabilities | 88 | 94 |
| Fixed Assets | 2 | 3 |
| Investments | 1 | 2 |
| Total Assets | 88 | 94 |
The balance sheet shows stable equity of ₹8 crore and modest reserve growth from ₹23 to ₹26 crore, while total assets rose to ₹94 crore from ₹88 crore. Borrowings increased slightly to ₹17 crore, but the low debt-to-equity ratio of 0.50 indicates minimal leverage. The capital structure remains conservative, with no signs of aggressive debt financing or large-scale asset acquisition.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +9 |
| Investing | -0 |
| Financing | -6 |
| Net Cash Flow | +2 |
👥 Shareholding Pattern
| Category | Q2FY25 | Q4FY25 | Q2FY26 | Q4FY26 |
|---|---|---|---|---|
| Promoters | 69.3% | 71.2% | 72.2% | 73.0% |
| FII | 0.5% | 0.6% | 0.6% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 12.8% | 11.2% | 11.8% | 11.3% |
| # Shareholders | 315 | 316 | 301 | 280 |
Promoter holding rose to 73.02% in Q4FY26 from 69.29% in Q2FY25, indicating accumulation by promoters, while institutional (FII/DII) ownership remains negligible at 0.61% and 0% respectively. Public shareholding declined slightly to 11.33% from 12.84%, and the number of shareholders decreased to 280 from 315, suggesting reduced retail interest. The trend reflects increasing promoter control and limited external investor engagement.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.63 L Cr | 38.3 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.43 L Cr | 83.2 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.1 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.15 L Cr | 34.0 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.00 L Cr | 91.8 | 20.8% | 20.6% | 0.45 |
| LUPIN | 98,305 | 17.4 | 27.9% | 24.7% | 0.26 |
| DRREDDY | 97,741 | 30.3 | 10.1% | 8.4% | 0.17 |
| MANKIND | 97,467 | 47.7 | 13.9% | 12.7% | 0.38 |
| AUROPHARMA | 96,836 | 26.3 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) High promoter concentration (73%) increases governance and control risk. 2) Absence of institutional or DII interest may signal lack of confidence from professional investors. 3) No disclosed use of authorized capital or convertible warrants raises concerns about potential dilution without clear value creation rationale. 4) Limited shareholder base (280) and low public float (11.33%) could lead to liquidity constraints.
🧠 Analyst's Read
The company is in a quiet phase focused on governance and capital structure adjustments, with no active growth narrative or investor outreach. Key next steps include the announcement of voting results and potential use of convertible instruments. Investors should monitor for clarity on capital deployment and any shift in institutional interest, but currently lack catalysts or forward guidance to drive re-rating.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd